It is suggested to expand the centralized collection of Chinese patent medicine and promote the high

Due to historical reasons, in the past, more than 400 varieties of traditional Chinese medicine formula granules were required to be developed by pilot enterprises. Subsequently, dozens of pilot enterprises approved by all provinces also followed the past, each of which exceeded more than 400 varieties. With the participation of more enterprises, each enterprise produces hundreds of formula particles. While forming a competitive pattern, the scattered situation of industry competing for raw materials, repeated research and development and repeated production is taking shape.

In this context, there are also some disadvantages. He said that due to the large variety of raw materials, enterprises were unable to establish controllable planting bases of raw materials and medicinal materials in the most advantageous raw material producing areas, resulting in the difficult guarantee of the quality of traditional Chinese medicine raw materials and the sharp rise and fall of prices, which affected the healthy development of the traditional Chinese medicine industry; The research and development of the production process of formula particles of various varieties is repeated and wasted. The research and development of one variety is less than hundreds of thousands of yuan. If there are hundreds of varieties, the investment will reach tens of millions or even hundreds of millions of yuan. Every enterprise simply repeats its research and development, resulting in a great waste of social resources, but there is no energy for in-depth research; The repeated production of various production enterprises, many varieties and non scale, resulting in the inability of all varieties to adopt the most advanced technology and special equipment, resulting in low-level duplication.

"The above problems cause a huge waste of human, material and pharmaceutical resources, which greatly restricts the healthy development of traditional Chinese medicine formula granules. In order to promote the healthy development of traditional Chinese medicine formula granules industry, it is suggested to clarify that traditional Chinese medicine formula granules can be circulated in a single variety, the approval qualification is not limited by the number of varieties, and enterprises are encouraged to make one or several best traditional Chinese medicine formula granules ； Promote the centralized collection of traditional Chinese medicine formula particles, which can enter the centralized collection of single varieties, give full play to the professional competitive advantage, and promote the healthy development of traditional Chinese medicine formula particles. "

Introduction: the centralized purchase of Chinese patent medicine is of great significance to promote the high-quality development of traditional Chinese medicine industry. In the past period of time, due to the needs of survival and development, Chinese patent medicine enterprises have made great efforts in drug sales, with a huge sales team, resulting in high sales costs, and some even rely on commission rebate promotion, increasing the medical burden. At the same time, the elements of high-quality development of enterprises - scientific and technological innovation and enterprise management improvement have been ignored. This will pose a great threat to the healthy and sustainable development of the Chinese patent medicine industry.

On the other hand, at present, the centralized purchase of Chinese patent medicine has just been launched in some provinces and cities, covering not enough provinces and relatively few drug varieties. The shortlisted rules for bidding enterprises in the pilot provinces of centralized purchase of Chinese patent medicine are different, but the previous performance scores of enterprises are too high in the link of technical evaluation, resulting in insufficient price competition in the bidding process The effect of centralized procurement with quantity is not fully played, and more truly competitive high-quality enterprises are not placed at the same competitive level, which affects the overall effect of centralized procurement and the goal of medical insurance cost control.

In this regard, the following suggestions are put forward: first, expand the variety range of centralized collection of Chinese patent medicines, accelerate the process of centralized collection of Chinese patent medicines everywhere, maximize the centralized collection of Chinese patent medicines as soon as possible, promote the high-quality, healthy and sustainable development of traditional Chinese medicine industry, and truly make traditional Chinese medicine benefit the Chinese nation. Second, further optimize the centralized volume procurement rules of Chinese patent medicines and the detailed rules for technical evaluation and price competition scoring, reduce the weight of technical evaluation, fully reflect the price advantage on the premise of ensuring the quality of drugs, so as to reduce the cost of medical insurance and realize the effect of scientific and fair competition. Third, bring traditional Chinese medicine formula granules into the scope of centralized collection to better promote the development of traditional Chinese medicine formula granule industry.